GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLY) » Definitions » Shareholder Yield %

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Shareholder Yield % : 0.35% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Shareholder Yield %?

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Clinuvel Pharmaceuticals's Shareholder Yield % was 0.35%.


Clinuvel Pharmaceuticals Shareholder Yield % Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Shareholder Yield % Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.07 0.05 0.19 0.24

Clinuvel Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.19 0.19 0.24 0.33

Competitive Comparison of Clinuvel Pharmaceuticals's Shareholder Yield %

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals's Shareholder Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Shareholder Yield % falls into.



Clinuvel Pharmaceuticals Shareholder Yield % Calculation

Clinuvel Pharmaceuticals's Shareholder Yield % for the quarter that ended in Dec. 2023 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.29 %+0 %+0.02 %
=0.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Clinuvel Pharmaceuticals  (OTCPK:CLVLY) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Clinuvel Pharmaceuticals Shareholder Yield % Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Shareholder Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Headlines

From GuruFocus

CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals

By Stock market mentor Stock market mentor 02-02-2023

CLINUVEL Trial Results Show Drug Reduces DNA Damage

By Stock market mentor Stock market mentor 01-16-2023

FDA Approves SCENESSE® For Genetic Disorder

By Marketwired Marketwired 10-09-2019

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-20-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 06-09-2022

3 High-Performing Stocks

By Alberto Abaterusso Alberto Abaterusso 07-12-2019

CLINUVEL to Trial Innovative Drug in Stroke

By Marketwired Marketwired 10-28-2020

Positive final results in stroke

By GuruFocusNews GuruFocusNews 05-04-2022